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In the drive to develop drugs with well-characterized and
clinically monitorable safety proﬁles, there is incentive to expand
the repertoire of safety biomarkers for toxicities without routine
markers or premonitory detection. Biomarkers in blood are
pursued because of specimen accessibility, opportunity for serial
monitoring, quantitative measurement, and the availability of
assay platforms. Cytokines, chemokines, and growth factors (here
referred to collectively as cytokines) show robust modulation in
proximal events of inﬂammation, immune response, and repair.
These are key general processes in many toxicities; therefore,
cytokines are commonly identiﬁed during biomarker discovery
studies. In addition, multiplexed cytokine immunoassays are
easily applied to biomarker discovery and routine toxicity studies
to measure blood cytokines. However, cytokines pose several
challenges as safety biomarkers because of a short serum half-life;
low to undetectable baseline levels; lack of tissue-speciﬁc or
toxicity-speciﬁc expression; complexities related to cytokine
expression with multiorgan involvement; and species, strain, and
interindividual differences. Additional challenges to their appli-
cation are caused by analytical, methodological, and study design–
related variables. A ﬁnal consideration is the strength of the
relationship between changes in cytokine levels and the de-
velopment of phenotypic or functional manifestations of toxicity.
These factors should inform the integrated judgment-based
qualiﬁcation of novel biomarkers in preclinical, and potentially
clinical, risk assessment. The dearth of robust, predictive cytokine
biomarkers for speciﬁc toxicities is an indication of the signiﬁcant
complexity of these challenges. This review will consider the
current state of the science and recommendations for appropriate
application of cytokines in preclinical safety assessment.
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One of the most facile tests of toxicity in vivo are changes in
blood biomarkers. The advantages of blood biomarkers include
quantitative measurement, accessibility, serial monitoring, fast
analytical turn-around time, and the availability of analytical
platforms. Blood-based markers have the potential for the
translation of preclinical risk assessment to the human patient
population as they are generally readily adaptedto clinical trials.
Presently, there is a shortage of adequately predictive blood
biomarkers that correlate with phenotypic manifestations of
several important drug toxicities. For example, there are no
validated blood biomarkers of vasculitis, lung toxicity (e.g.,
interstitialpneumonitis),idiosyncraticliverinjury,andtesticular
toxicity (e.g., sertoli cell toxicity and germ cell degeneration).
There is encouragement by regulatory agencies to use sensitive
and predictive tests to identify early and clinically monitorable
toxicity for successful development and registration of innova-
tive and safe drugs (Woodcock and Woosley, 2008). Identiﬁca-
tion and understanding of potential toxicities during drug
discovery and early development permit accelerated attrition of
drug candidates and the opportunity to improve chemical
selection through structure-toxicity modeling when such activi-
ties are fully supported. The Critical Path initiative by the U.S.
Food and Drug Administration (FDA, 2006) has encouraged this
approach in their 2006 report, ‘‘Innovation or Stagnation: Critical
Path Opportunities Report and List.’’ This report acknowledged
the gaps extant in toxicity detection using the current toolbox of
routine safety biomarkers (e.g., standard clinical pathology
parameters) and fosters the advancement of development
science in many areas, including biomarker discovery and use.
A biomarker qualiﬁcation process has evolved from this
initiative. The process begins with a voluntary submission to
regulatory authorities of a novel biomarker and the context of its
application by consortia, industry, government, academic, or
clinical researchers, followed by a data package (Goodsaid et al.,
2008). The test case for this process has been the submission of
scientiﬁc data on several novel renal toxicity biomarkers by the
Critical Path Institute Predictive Safety Testing Consortium to the
European Medicines Agency and the FDA, which led to the
acceptance of these markers for use in preclinical drug
development (EMEA, 2008).
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(hereafter collectively referred to as cytokines) as safety bio-
markers has been fueled by mechanistic and exploratory
biomarker studies that insinuate inﬂammatory and repair pro-
cesses in toxicity. Discovery techniques, such as RNA expression
analysis, proteomics, and preconﬁgured multiplex cytokine
assays, may disclose increased or decreased values for various
cytokines in animals with toxicity. When there is no premonitory
biomarker for a speciﬁc toxicity in routine panels, these factors
are often proposed as biomarkers for the toxicity. Although there
is great desire and technological capability around the potential
use of cytokines as safety biomarkers, based on our current
scientiﬁc knowledge and experience, what practical potential do
these factors have in becoming qualiﬁed toxicity biomarkers for
preclinical risk assessment and in a patient population?
This review will examine the conceptual utility of cytokines
as in vivo biomarkers of toxicity in preclinical drug de-
velopment. In particular, consideration will be given to (1) the
underlying natural biology of cytokines, (2) analytical and
methodological factors in biomarker qualiﬁcation, (3) evalua-
tion in the established preclinical in vivo study designs, and (4)
relationship between changes in cytokine levels and association
with morphological or functional manifestations of toxicity.
These considerations will be described in the context of using
systemic (blood) levels of cytokines as exploratory biomarkers
for the toxicity of protein therapeutics and small molecules.
CHARACTERISTICS OF A TOXICITY BIOMARKER
A biomarker is deﬁned as any measurable biological char-
acteristic encompassing the detection of physiologic, pharmaco-
logic, and pathologic processes (Biomarkers Deﬁnitions Working
Group, 2001). A toxicity (or safety) biomarker will either directly
reﬂect or predict susceptibility to a structural and/or functional
consequence of exposure to a chemical or biologic therapeutic.
When the toxicity biomarker is involved in the mechanism of
action of the pharmacological agent, the marker is also
a pharmacodynamic (PD) end point. In this instance, there will
be a continuum from pharmacology to toxicology and the
thresholds will be set in accordance to routine toxicity end points
such as histopathology and clinical pathology (clinical chemistry,
hematology, urinalysis, and coagulation) and/or demonstration
of a level (i.e., a decision limit) beyond which the response is
nonreversible and deleterious. Toxicity biomarkers that are not
directly related to the desired pharmacologic activity of the drug
constitute off-target activity or a secondary (indirect) pathologic
process. In this circumstance, the biomarker is purely a signal of
toxicity. When the indirect toxicity depends on complex
biological interactions between organ systems in vivo,t h em a r k e r
may behave differently across species and be contingent on other
study design variables.
Desirable characteristics of a toxicity biomarker include
speciﬁcity and early detection of toxicity (i.e., sensitivity) with
a magnitude of change sufﬁcient to distinguish from biological
variability. The half-life of a serum biomarker should allow
a practical window for detection, yet be responsive to the
changing state of the injured tissue with adequate stability
in vitro. Premonitory biomarkers, those that precede the
manifestation of a histological lesion and predict severity, are
clearly valuable for translation to a clinical population and could
expedite risk assessment and dosing decisions, i.e., to stop or
decrease the dose.
Safety biomarkers measured in blood and other body ﬂuids
provide the opportunity for serial monitoring and could
potentially reduce the numbers of animals used if the detection
of toxicity relied solely on microscopic examination of tissue
collected at necropsy. Quantiﬁable biomarkers allow inference
of severity and reversibility of toxicity. Markers that are
continuous variables and correlate with microscopic severity
and/or loss of function can be used in modeling of dose-
response-toxicity relationships to better deﬁne safety margins
and risk-beneﬁt characterization.
Novel preclinical safety biomarkers are qualiﬁed by correlation
to an established toxicity end point, e.g., tissue histopathology,
clinical pathology parameters, and/or functional tests in animal
toxicity studies. Time course and dose-response studies across
species with robust positive and negative controls allow
evaluation of the performance of the marker in preclinical
development. In general, the applicability of a novel toxicity
biomarker to clinical trials will center on a comparable biological
response between nonclinical species and humans, invasiveness
of the procedure, and availability of the technology and expertise.
Thus, a minimal expectation for the use of cytokines as
safety biomarkers is that they are speciﬁc, sensitive, and show
reliable temporal kinetics that permit detection, persistence,
and resolution of toxicity.
CONSIDERATIONS RELATED TO CYTOKINE BIOLOGY
Cytokines are a diverse group of soluble peptides that signal
between cells and elicit biological responses, including but not
limited to cell activation, proliferation, growth, differentiation,
migration, and cytotoxicity. Classically, cytokines were under-
stood in the context of the immune response, whereby sequential
cytokine secretion orchestrates inﬂammation and immunity.
T-lymphocyte cytokines divine the Th1 (interferon gamma,
IFNc, and interleukin 12, IL12), Th2 (IL4, IL5, IL6, and IL13),
Th17 (IL17, IL21, and IL22), and T-regulatory (transforming
growth factor beta, TGFb, and IL10) subsets of T cells that
stimulate or modulate the adaptive immune response to infectious
agents and other antigens. Macrophages and injured cells secrete
chemotactic (chemokines) and proinﬂammatory cytokines to
elicit the innate immune response to sites of active inﬂammation.
Furthermore, colony-stimulating factors and interleukins harmo-
nize myelo- and lymphopoiesis to populate these cellular
responses. Under the cytokine umbrella of 5–70 kD, soluble
mediators are an extensive network of peptide and glycopeptide
families comprising interleukin, interferon, chemokine, tumor
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derstanding of cytokine biology underscores their pleiotropic
and redundant functionality, widespread expression by non-
hematopoietic cell types, and roles outside of immunity in
development, reproduction, endocrine regulation, and metab-
olism (Papanicolaou et al., 1998). A number of cytokines can
therefore deﬁne a pathologic response but not necessarily
at i s s u es i t eo ft o x i c i t y .
Cytokines function as autocrine (secretion and stimulation of
the same cell), paracrine and juxtacrine (stimulation of nearby
cells), or endocrine signals (circulating in the peripheral blood to
act on cells remote to the source of production). The majority of
cytokines have induced expression and are secreted or trans-
located to the cell membrane upon translation (Haddad, 2002).
Cytokines such as TGFb and platelet factor 4 (PF4)/CXCL4 are
stored in secretory vesicles (in this case platelet granules) for
immediate release upon cell activation. Generally, these factors
act locally at nano- to picogram per milliliter concentrations have
a short half-life and transient activity. These low concentrations
and predominately local activity may produce little change in
cytokine levels in the systemic circulation despite considerable
local perturbation. As an example, IL13 is important in the
pathogenesis of asthma and there is interest to explore its use as
a systemic disease biomarker of asthma as well as a PD
biomarker for therapeutics targeting IL13 (St Ledger et al.,
2009). An assay with improved sensitivity for detecting serum
IL13 showed no difference in the systemic levels of IL13 in
symptomatic asthmatics compared with asymptomatic asth-
matics and healthy controls (St Ledger et al., 2009). At least in
the cohorts tested in this study, serum IL13 was not a biomarker
of asthma. Notable exceptions to this general scheme of local
activity are the hematopoietic cytokines (e.g., erythropoietin) that
act as endocrine factors to maintain homeostatic set points of
blood cells and have a measurable basal blood level.
The cytokine cascade mode of action is illustrated by the
inﬂammatory response. The primary proinﬂammatory cytokines,
comprising TNF-a, IL1, and IL6, are expressed sequentially and
amplify cellular activation and recruitment to generate additional
cytokines and chemokines. Anti-inﬂammatory cytokines, prin-
cipally the IL10 family, are produced early to downregulate
proinﬂammatory cytokines, and TGFb expression contributes to
resolution and tissue repair phases. Cytokine cascades result in
a staged appearance and disappearance of cytokines in the local
and systemic environments, with primary cytokines that drive the
early response and are more commonly detectable in peripheral
blood. Dysregulation of these cascades can lead to autoimmune
disease and hypersensitivity.
Apart from mediating overt immune responses, cytokines play
a role in physiological processes. Cytokines participate in
maintenance of organ structure and function by tissue-resident
macrophages and restoration of homeostasis during ‘‘para-
inﬂammatory’’ states of cell stress (Medzhitov, 2008). Prominent
examples of such physiological roles include maintenance of
vascular integrity, the interplay of energy metabolism with the
immune system, and neurohumoral stress (Medzhitov, 2008).
These activities are theorized to occur largely on a tissue level
and are mediated by resident tissue macrophages; any
contribution to systemic cytokine levels is unclear.
Cytokine receptors are classiﬁed by structural similarities and
are primarily cell surface receptors. Soluble receptors can have
agonist and antagonist cytokine signaling activity and confer
cell extrinsic signaling receptivity to cytokines, e.g., cardio-
myocyte hypertrophy in response to soluble IL6 receptor
ligation (Papanicolaou et al., 1998). The presence of soluble
receptors is also a point of regulating cytokine activity.
Cytokine receptors are composed of subunits that form higher
order complexes following cytokine binding. The largest
receptor class are nontyrosine kinase class I and II receptors
that signal through the JAK/STAT pathway. Class I receptors
bind the hematopoietic cytokines and many of the interleukins.
Heterodimeric class I receptors combine a ligand-speciﬁc
subunit with a shared signaling receptor (e.g., common beta
and gamma chains, and gp130). Other receptors include class II
receptors that bind the interferon and IL10 families, the
immunoglobulin superfamily receptors that bind the IL1
cytokine family, TNF family receptors, TGFb receptors, and
the G-protein–coupled chemokine (or rhodopsin superfamily)
receptors (Haddad, 2002). The common use of receptors by
cytokine families often confers overlapping signaling outcomes.
Pleiotropy (multiple actions) and redundancy (overlapping
actions) are characteristic of cytokine biology. As discussed,
shared receptors are a point of integration for multiple cytokine
ligands and contribute to redundancy. Pleiotropy occurs when
shared receptors modulate different downstream signals de-
termined by a cytokine’s concentration, its relative receptor
subunit afﬁnity, and the cell type acted upon. For example,
crystallographic analysis of the shared use of receptors by IL4
and IL13 demonstrates that differences in the structural
dynamics of receptor-cytokine engagement can specify unique
signaling outcomes even when an identical receptor hetero-
dimer in a deﬁned cell and context is engaged (LaPorte et al.,
2008). Additional modiﬁers will include the presence and
concentration of other local cytokines and the growth and
activation state of the cell (Haddad, 2002). Transitory lateral
communication and cross talk with noncytokine receptors also
expand the signaling outcome (Bezbradica and Medzhitov,
2009). IL6 exempliﬁes pleiotropic action by exerting proin-
ﬂammatory, anti-inﬂammatory, endocrine, and metabolic
effects. These multiple responses include induction of the
acute-phase response (e.g., C-reactive protein, ﬁbrinogen),
activation of the hypothalamic-pituitary-adrenal axis (with
attendant anti-inﬂammatory affects), growth hormone secre-
tion, and reduction of human serum cholesterol (Papanicolaou
et al., 1998). These attributes of pleiotropy and redundancy
have implications for the evaluation of cytokines as bio-
markers. As a number of cytokines may cause similar
responses such as TNF-a, IL1, and IL6, they can be interpreted
collectively as markers of inﬂammation. On the other hand,
6 TARRANTeach cytokine may have multiple actions, the example given is
IL6, and thus lack speciﬁcity for one outcome alone.
Cytokine expression and activity are highly regulated to
constrain a system that has potential for immunopathology.
Only brief mention of some mechanisms is made here and the
reader is referred to review articles (Bonecchi et al., 2009;
Haddad, 2002; Medzhitov and Horng, 2009). Cytokine
networks trigger several members that downregulate the
cascade to self-limit a response, i.e., IL10 and TGFb. Cytosolic
regulation of receptor activity is primarily by the suppressor of
cytokine signaling (SOCS) family with contribution also by
protein tyrosine phosphatases and protein inhibitor of activated
signal transducer and activator of transcription (PIAS)
members. The onset and level of cytokine production are also
inﬂuenced by posttranscriptional processing by adenine- and
uridine-rich elements in the 3# untranslated region of
messenger RNA (Anderson, 2008). In the extracellular
environment, proteases can regulate cytokine activity and
provide a checkpoint for activation of latent factors, i.e., TGFb.
The short half-life (usually < 1 hr) of these peptides and the
presence of binding proteins and decoy receptors also attenuate
functional activity of cytokines extracellularly.
There are species homologues for the majority of cytokines;
however, some surprising differences in phylogenetically highly
related species are observed. Polymorphisms in the TNF
promoter differ between nonhuman and human primates and
between primate species and subspecies (Baena et al.,2 0 0 7 ). For
example, divergence in the promoter can alter the binding
afﬁnity of transcription factors and transcriptional activation of
the TNF gene in response to lipopolysaccharide (Baena et al.,
2007). Functional single nucleotide polymorphisms of cytokine
genes in the human population can result in different levels of
expression in healthy individuals and have disease associations
with autoimmunity, susceptibility to infection, cardiovascular
disease, and cancer (Smith and Humphries, 2009). Cytokine
gene polymorphisms in preclinical toxicity species are not well
described. An investigation comparing polymorphisms in the
regulatory regions of the rat TNF-a gene and in vitro TNF-a
release to splenocyte stimulation failed to show a relationship
(Warle et al.,2 0 0 5 ). Cytokine genes also have different
conservation across species. Rodents do not have an ortholog
of the human IL8 gene; rather, the mouse KC gene and the rat
cytokine-induced neutrophil chemoattractants (CINC) family are
possibly examples of convergent evolution to produce a neutro-
philic chemotactant (Modi and Yoshimura, 1999). These species,
subspecies, and strain differences, often not appreciated because
of the emerging nature of cytokine analysis in the systemic
circulation, require a circumspect approach to cytokine bio-
marker translatability to humans.
Biological variability of cytokines, also referred to as inter-
and intraindividual or between and within subject variability, has
not been extensively evaluated in healthy animals or humans.
Analysis of IL13 serum levels showed a 10-fold interindividual
variability in healthy subjects (< 0.07–1.02 pg/ml). The intra-
individual variablility of serum IL13 in asymptomatic asthmatics
(whom had no apparent association between serum IL13 and
disease) was up to threefold over a 15-day period (St Ledger
et al.,2 0 0 9 ). Circadian rhythm has also been exhibited by
proinﬂammatory cytokines and linked to changes in corticosteroid
and melatonin levels over the 24-h day cycle. Blood levels of
IL1, IL6, IFNc,a n dT N F - a are highest in the morning (de Jager
and Rijkers, 2006). Fascinating is the recent work that establishes
the presence of local and cell-autonomous circadian rhythms in
lymphoid organs and peritoneal macrophages (Keller et al.,
2009). The occurrence of circadian rhythm may contribute not
only to changes in measured cytokines at different times of
the day but also to the effectiveness and nature of the immune
response.
In the context of multiple organ toxicity, key aspects of
cytokine biology (pleiotropy, redundancy, and tiered expression)
may lead to similar (primary) cytokines showing measurable
changes in blood yet not disclosing tissue-speciﬁc differences in
toxicity. As much of the biological activity of cytokines occurs at
a cellular level in local environments, elevations may not be
detected in the systemic circulation.
METHODOLOGICAL CONSIDERATIONS FOR CYTOKINE
MEASUREMENT
Quantiﬁcation of soluble cytokines is performed largely by immuno- or
bioassay. In contrast to an immunoassay that quantiﬁes the peptide, bioassays
demonstrate functional activity of the cytokine. However, as bioassays are not
readily scalable or standardized and vary in speciﬁcity, the remaining
discussion will focus on immunoassays as a more robust format for cytokine
measurement in preclinical drug development. Technological advancements in
immunoassays have led to improved detection sensitivity and attendant
miniaturization, automation, and multianalyte formats. In a less concerted
effort, attention has also been directed toward deﬁning the immunoreactive
component measured in the assay. The latter concept is explored in greater
depth in the following section on method validation.
Platforms can be categorized into those with solid-based supports for the
capture antibody, such as a plastic plates and tubes, membranes, and glass
slides, or suspension systems using antibody-coupled beads. The conventional
ELISA format of a two-site immunometric ‘‘sandwich’’ assay conducted in
a microtiter plate and detecting a single analyte can optimally achieve detection
limits in the low to mid picogram per milliliter over a ~2 log working range.
Bead-based suspension systems address some limitations of the conventional
ELISA, e.g., sample volume requirement and assay run time, by increasing the
available surface area for the antigen-antibody reaction and employing faster
ﬂuid-phase reaction kinetics (Kellar and Iannone, 2002). Detection systems also
differentiate platforms. Fluorescence and chemiluminescence have led to
claimed sensitivity of single digit picogram per milliliter cytokine concen-
trations and a 4–5 log working range. A new approach uses digital counting to
measure individual ﬂuorescently tagged antigen-antibody complexes in the
suspension phase to improve sensitivity (St Ledger et al., 2009).
Multiplexed assays represent a major advance in the measurement of
cytokines. In a multiplexed assay, many different cytokines can be measured
simultaneously in one specimen aliquot. Common multiplex platforms are ﬂow
cytometric assays with ﬂuorescent microspheres and capture antibody-spotted
plate-based assays. Clear advantages are obtained through specimen conservation
and labor and timesavings. These features make multiplexes a useful screening
tool. In combining multiple different antigen-antibody reactions into the one
assay, compromises to assay factors such as incubation time, buffers, and
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analytes (cytokines) together. Such compromises can result in reduced sensitivity
and/or dynamic range for some markers and variation between different
multiplexes. A method comparison study between a popular electrochemilumi-
niscent plate (MSD) and ﬂuorescent bead (Luminex) platform demonstrated
superior sensitivity and accuracy with the MSD assay and better precision
(reproducibility) with the Luminex assay (Chowdhury et al.,2 0 0 9 ). There have
been varied conclusions regarding comparability of the ﬁndings when clinical
blood specimens have been evaluated by several multiplex platforms and single
analyte ELISA. Results will be inﬂuenced by the number of cytokines tested, the
platforms chosen, the number of specimens analyzed, and type and severity of the
disease state or response in the individual (Khan et al.,2 0 0 4 , 2009; Toedter et al.,
2008). Generally, different platforms (i.e., bead, plate, single analyte, and
multiplex) and assays (i.e., different manufacturers within a platform) are broadly
comparable, showing similar trends and response proﬁles. However, absolute
values will usually differ and discrepancies for individual cytokines are not
unexpected. Most divergence between assays is likely to occur for cytokines with
low to undetectable concentrations in the blood of healthy subjects. A robust
approach to selecting the most reliable and informative assay for the toxicity
under investigation is to evaluate several assays on specimens reﬂecting the
intended study set prior to analyzing a large study.
Assay automation will inﬂuence platform and, possibly, biomarker selection.
Manual assays (e.g., a plate-based sandwich ELISA) can be semiautomated with
robotics for sample preparation, reagent mixing, incubation, washing, and signal-
detection steps. Automation should improve precision by eliminating manual
pipetting steps and reduce other sources of random error by minimizing
procedural variations. An automated platform could also facilitate the transfer of
the safety biomarker into clinical laboratories for clinical trial work. In a realistic
scenario, discovery would take place on manual assays to decrease the time to
implementation and allow comparison of various assays. The move to automation
would occur at later stages of qualiﬁcation when the biomarker is more promising,
assay selection has been made, and the studies are larger and/or more frequent.
In summary, cytokines can be measured in standard single anlayte ELISA or
as multiplexed plate or bead-based assays evaluate many cytokines at once.
Multiplexes provide a convenient and cost-effective approach and useful
screening step in early biomarker discovery. As much of the assay performance
is conditioned on the speciﬁcity and afﬁnity of the antibody reagents, platform
choice should be evaluated on the merit of the particular assay for the analyte
under examination: there is no clearly superior system.
HOW ASSAY PERFORMANCE AND METHOD VALIDATION
AFFECT BIOMARKER DISCOVERY
The method validation of an assay is evaluated by determining a number of
parameters including accuracy and precision. This is distinguished from
biomarker qualiﬁcation (the commonly used terminology) that determines the
association of a biomarker with a phenotypic end point. The level of assay
validation, and the criteria for acceptance, will depend on the stage of drug
development, so called ‘‘ﬁt for purpose.’’ Less rigor is advocated in early
preclinical drug development with regard to the resources and time required for
advanced method validation and the criticality of the decision based on the
assay (Lee et al., 2005). In the context of cytokine immunoassays, several of
these validation criteria should be better understood by those unfamiliar with
assay development but who inﬂuence biomarker selection and interpret the data
generated in preclinical studies. The following discussion highlights concepts
pertinent to cytokine biomarker discovery and qualiﬁcation; more detail on this
topic is found in a position paper on assay validation of biomarkers in drug
development (Lee and Hall, 2009; Lee et al., 2005).
In comparison to routine serum biomarkers, i.e., the clinical chemistry panel,
there is often a lack of assay standardization for cytokines. This is a major
reason that assays differ in the measured value for a cytokine in the same
specimen. Calibration of the assay is usually done with recombinant protein in
buffer that does not represent the native specimen. Such assays provide relative
quantiﬁcation rather than deﬁnitive or absolute values. As there is no reference
standard, and calibrators will vary among assays, values obtained from different
assays will not necessarily agree. Accuracy is thus a relative term in the absence
of standardization. Changes in recovery and a lack of linearity may occur as
a consequence of binding proteins, complex formation, and undeﬁned
interferants in the blood. It is advisable to prospectively optimize dilutions
that will be applied to specimens from studies to verify manufacturer’s claims
and/or establish basic assay performance criteria.
Precision, both within a run and between runs or days, should be veriﬁed
prior to assay implementation. Precision is usually expressed as the coefﬁcient
of variation and can be more important than the problematic criterion of
accuracy. A precise assay will provide reproducible results within and between
studies and demonstrate relative response, i.e., fold change, and patterns of
response for potential biomarkers. Analytical coefﬁcient of variations ranging
from 18 to 44% for different cytokines were found for one multiplex (Wong
et al., 2008). Yet this degree of analytical imprecision was still less than
individual (biologic) variation, permitting real differences in cytokine values to
be detected in the population tested (Wong et al., 2008). Generally, an assay for
a novel biomarker should have < 25% imprecision (Lee et al., 2005), although
there is no hard rule. Quality control (QC) material derived from pooled
specimens aliquoted and run on each plate is very useful in both conﬁrming
precision during assay validation and bridging results between studies
(Chowdhury et al., 2009; Lee and Hall, 2009). These are a very useful extra
layer to the QC material that, although sometimes provided by the assay
manufacturer, are not entirely representative of the native matrix of study
specimens and are subject to lot and source changes. Knowing or establishing
the expected biologic variation for a cytokine biomarker and degree of change
that corresponds to toxicity will assist in setting this assay performance goal.
The manufacturer (or developer) should provide data on the speciﬁcity of
the assay for the cytokine under examination, i.e., the percentage of the
principle analyte and other structurally related peptides detected by the assay.
This is crucial in multiplex assays that could be measuring structurally similar
analytes simultaneously. Also, knowledge of the speciﬁc form of the cytokine
measured impacts evaluation of the cytokine as a biomarker in several ways:
by testing the correct form of the cytokine in a hypothesis-driven experiment,
accurate description of a putative cytokine biomarker discovered in
a nonhypothesis-driven experiment, and comparing cytokine ﬁndings across
studies when different assays are used. The measurement of TGFb is
instructive in this regard. Circulating TGFb comprises several isoforms as
well as latent and active peptides and heterogeneous complexes of these peptides
(Grainger, 2007). Groups investigating the association of TGFb with
atherosclerosis have reported increases, decreases, or no change in blood levels
of ‘‘TGFb,’’ likely because of their measuring different forms (Grainger, 2007).
A basic approach here is to know the immunoreactive component or form of the
peptide assayed. When that information is lacking, knowledge of the circulating
forms and biological action of the cytokine will determine whether a greater level
of detail is required to accurately deﬁne the biomarker.
Information on the species cross-reactivity of an immunoassay is sometimes
lacking. Characterization of mouse cross-reactivity may be provided; however,
this is no guarantee that the antibodies detect rat peptides. Similarly, reactivity
with human proteins does not imply detection in nonhuman primate specimens.
Species cross-reactivity should demonstrate recovery of the protein in the native
matrix and the lack of detection when the analyte is absent or intentionally
depleted. Experiments using recombinant proteins in buffer are an approximation
and do not account for both the heterogeneity of posttranslational modiﬁcations in
the protein and the interferants present in native specimens.
Reporting of the lower end of the working range of the assay is fraught with
misunderstanding and vitally important for distinguishing ‘‘trends’’ at low
concentrations. Strictly, the lowest reportable value, or lower limit of
quantiﬁcation (LLOQ, also referred to as functional sensitivity), should at
least meet a predetermined precision and accuracy criteria, i.e., ± 30% (Lee
et al., 2005). This will usually have to be established by the laboratory with
a precision curve deriving the precision limits for each point of the calibration
curve. Manufacturers often only provide a limit of detection (LOD, also
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blank, and sensitivity), which pertains to the noise of the assay and is calculated
as 2 or 3 SD from the average signal of the buffer (or blank). Values for an
analyte that are above but close to the LOD are imprecise and inaccurate until
proven otherwise, and much care should be taken both in the reporting and in
the interpreting results without knowledge of the LLOQ.
In addition to the aspects of analytical validation outlined above, controlling
variability associated with specimen collection and handling should commence
at early stages of safety biomarker exploration and qualiﬁcation. Preanalytical
aspects such as the matrix (serum or plasma) and type of anticoagulant, blood
tube, collection site, and processing time should be determined and
standardized as soon as feasible. Several cytokines can be degraded in vitro
during delayed sample processing and are more stable in EDTA or citrated
plasma (Niwa et al., 2000). Degranulation of platelets and white blood cells
(and residual contamination of cells in plasma) may also alter serum as
compared with plasma concentrations of several cytokines (Boehlen and
Clemetson, 2001; Grainger, 2007; Hosnijeh et al., 2009; Wong et al., 2008).
The potential inﬂuence of anticoagulant on cytokine values measured by
multiplex immunoassays is shown in Table 1. Wong et al. (2008) found only 3
of 10 cytokines (IL4, IL6, and IL8) had signiﬁcant correlation between serum
and plasma, although this comparison was made in healthy human volunteers
with low levels of cytokines and thus a limited range of values. The table
suggests that values in plasma often exceed serum, although there is no clearly
superior matrix for cytokine measurement in published studies. Serum is often
a pragmatic choice for combining with collections for clinical chemistry and
applicability in the clinic.
Tube type can also affect the levels of low-abundant analytes (Ray et al.,
2005) and at the very least, the use of nonstandard tubes is discouraged.
Specimen stability should also be considered and lengthy storage periods
avoided when there is insufﬁcient information available. Several major
inﬂammatory cytokines show little thermal lability and resist several freeze-
thaw cycles (Kenis et al., 2002), although this may be epitope dependent (Ray
et al., 2005). It should be appreciated that the sooner a specimen matrix and
tube type are speciﬁed, and stability deﬁned, the variation within and between
studies is reduced and study data are maximized. The investigator can more
rigorously reanalyze previously collected specimens to bridge results for
changes in assay or extend the number of markers analyzed retrospectively.
Last, the challenges of developing a multiplex assay for later regulatory
work should be considered during selection of a panel of biomarkers. The most
pertinent guidance the FDA (2007) has for multiplex immunoassays pertain to
pharmacogenetic tests. There has been little pressure testing of immunoassay
multiplexes in a regulatory environment. Ellington et al. (2009) performed
a large-scale study with human plasma specimens run on two planar plate-
based multiplexes that included several cytokines and multiple QC materials.
They found potential issues with imprecision, an unidentiﬁed systematic bias
between plates, and QC failures. On the other hand, Ray et al. (2005) validated
a 5-plex bead-based assay and showed acceptable assay performance. The
group drew attention to postanalytical data management requiring additional
points of QC and process management for this assay format.
Method validation occurs incrementally during biomarker discovery and
qualiﬁcation. Understanding key features of cytokine assay performance,
particularly precision, speciﬁcity, and LLOQ, will allow more informed assay
selection and evaluation of data generated during biomarker discovery.
Manufacturer’s claims of assay performance should be veriﬁed prior to assay
implementation and specimen matrix and stability deﬁned early to increase the
quality of the data generated during biomarker discovery and evaluation.
THE INFLUENCE OF PRECLINICAL TOXICITY STUDY
FACTORS ON CYTOKINE INTERPRETATION
The biology of a cytokine can be altered in a toxicity study
by the inﬂuences of the physicochemical properties of the
biologic or pharmaceutical agent, pharmacokinetics, and/or the
perturbation of the system associated with pharmacological and
toxicological effects. The design of toxicity studies, in particular
the primacy of collecting a standard set of end points to assess
toxicity, also imposes constraints on the blood collection
schedule and blood volume removed. A stepwise biomarker
qualiﬁcation process in the preclinical space, analogous to the ﬁt
for purpose assay validation approach (Lee et al.,2 0 0 5 ), is
advocated to determine how the putative biomarker performs in
different study designs, species, and in lockstep with increasing
regulatory rigor during drug development (Fig. 1).
The progress of a therapeutic agent through preclinical
development in vivo follows a path of increasing study length
and more comprehensive end point analyses. Pharmacokinetic
studies offer a short window into acute effects of the drug
(usually over 24 h) and a view of PD and safety signals in
d i f f e r e n ts p e c i e s .T h i st i m ec o u r s es t u d yi sau s e f u ld e s i g nf o r
capturing cytokine modulations and relating changes to both PD
markers and drug exposure. As the intent is not to deﬁne toxic
doses, there may be little in the way of detectable cytokine
changes at the exposures tested. Single dose tolerability studies
for small molecules do provide an opportunity to sample the
animal for toxicity biomarkers with respect to driving the system
to toxic thresholds. Important considerations in the interpretation
TABLE 1
Matrix and Anticoagulant Affect on Cytokine Values Measured
by Multiplex Immunoassay in Humans
Higher
a Equivalent
b < 50% Reported
c
IL1a C
d,H
d,S
d
IL1b C
d;A
e H
d;S
e
IL2 A
e C
d,H
d,S
d S
e
IL4 A
e,( H
e)C
d,H
d,S
d
IL5 C
d,S
d;A
e,( H
e)H
d,S
d S
e
IL6 C
d;A
e H
d,S
d, e
IL7 A
e,( H
e)
IL8 H
e,S
e C
d,H
d,S
d, e
IL10 A
e,( H
e)C
d,H
d,S
d
IL12 A
e,( H
e)C
d,H
d,S
d
IL13 C
d;A
e,( H
e)H
d,S
d
IFNc A
e,( H
e)C
d,H
d,S
d
TNF-a C
d;A
e,( H
e)H
d,S
d
RANTES C
d,H
d,S
d
Eotaxin H
d C
d,S
d
Note. A, acid citrate dextrose plasma; C, citrate plasma; H, lithium heparin
plasma; S, serum.
aCytokines with geometric mean or median values (depending on study) that
exceed by   40% the value in the next highest matrix. When the second highest
value also exceeds by 40% the third matrix, this matrix is in parentheses. 40%
chosen to exceed the analytical variability (except IL13 in Wong et al., 2008).
bCytokine geometric mean or median value (depending on study) is within
40% of the highest value for the cytokine.
cValues not reported are beyond the working range of the assay, i.e., below
the lower limit or above the upper limit of detection.
dHosnijeh et al. (2009).
eWong et al. (2008).
BLOOD CYTOKINES AS BIOMARKERS 9of cytokines in these acute studies are the impact of stress,
diurnal variations of the analyte, and blood volume removed.
A single, large volume of blood collected has been shown to
induce cytokine gene expression in the liver and lung of mice
(Rajnik et al., 2002). Excitement and stress triggered in toxicity
studies with handling, blood collection, and tissue damage have
the potential to increase expression of IL6 (Papanicolaou et al.,
1998). In using pharmacokinetic and tolerability studies as
opportunities for biomarker discovery, it is important to control
some of the study-related variables that may impact cytokine
expression independent of the therapeutic agent. Baseline
cytokine blood levels (predose) should be taken on all animals
to control for individual differences not related to the drug.
However, baselines alone may not be sufﬁcient to control for
diurnal changes, different stress levels during the study,
individual biological variability unrelated to the therapeutic,
and progressive blood volume reduction. Contemporaneous
vehicle-treated control animals matched for age and sex, with
a similar group size, are therefore a necessary additional control
for these factors. Another key strategy is to reduce analytical
variability by ensuring that specimens over the entire time course
and between groups are randomly allocated to assay runs.
Multidose studies, usually ranging from several weeks to
months, are conducted to evaluate toxicity associated with
prolonged drug exposure and support human dosing of the
therapeutic agent. Incorporating biomarker discovery and
qualiﬁcation into this study type permits longitudinal analysis
and the association of the biomarker with subacute and
subchronic toxicities. Biological variability in the levels of
cytokines related to aging and ovarian cycles (Brannstrom
et al., 1999; Cannon, 2000) may become evident in the longer
multidose study format. As depicted in the schematic for
preclinical toxicity biomarker qualiﬁcation (Fig. 1), a study
with limited, i.e., single organ, versus complex (multiorgan)
toxicity necessitates a higher degree of assay validation and
study rigor, i.e., controls, to support biomarker evaluation.
Suggested time points for cytokine analysis are baseline
(prestudy), predose, and postdose. The predose sampling is
useful over longer studies to capture a shifting baseline or
persistence of previous recorded changes in cytokine levels.
Postdose time points are typically acute and multiple, e.g.,
1–6 h and 24 h, and may be informed by the time to maximal
concentration in blood of the therapeutic agent or data from
previous biomarker studies of cytokine response kinetics to the
toxicity under investigation. This multisampling paradigm
accommodates the transience of biomarker changes and the
potential for a modiﬁed cytokine response in the transition from
acute to chronic (long-standing) toxicities, reﬂecting the altered
cellular and tissue environment. Collecting sufﬁcient blood for
reanalysis of specimens by a second platform is best practice
but entirely contingent on the stage of qualiﬁcation of the
biomarker and the size of study animals. Blood volume limita-
tions, dependent on the animal size and species, may not
accommodate the proposed cytokine biomarker collection
schedule. Species selection (large vs. small animal), use of
larger animals with a greater circulating blood volume, dividing
time points into cohorts, and satellite groups are strategies to
not exceed blood volume restrictions.
FIG. 1. Preclinical toxicity biomarker qualiﬁcation.
10 TARRANTThe rigor of multidose studies can also beneﬁt biomarker
discovery and qualiﬁcation by decreasing variability. Stan-
dardized processes that decrease variability include speciﬁed
blood collection time points in relation to both time of day,
dosing, feeding, speciﬁed collection sites, anesthetic regimens
(if used), specimen matrix, and blood processing and handling
procedures. Use of vehicle-control animals, typically included
in multidose toxicity studies, are key to account for biological
variability when interpreting cytokine data. A power analysis
leveraging what is known on biological variability or cytokine
response can also select the appropriate number of animals to
demonstrate a drug-related change in cytokine value. Similar to
the recommendation for biomarker discovery in single dose
studies, random assignment of specimens to assay runs is
advised. In these longer studies, specimen stability should be
conducted prestudy to facilitate the suggested randomization of
specimens from time points and groups; in addition, QC
materials in relevant species and strain matrix should be
included in each run to accept runs and bridge results within
a long or large study.
Misinterpretation of biomarker data can occur when
pharmacological or toxicological responses in vivo result in
factors that interfere with cytokine assays. Analytical in-
terference attributable to the physicochemical properties of the
therapeutic should be addressed prestudy to assist in selection
of an assay or to develop techniques to circumvent the
interference. Cytokine analogues can generate anticytokine
antibodies both to the protein therapeutic itself (de Lemos
Rieper et al., 2009) or to the structurally similar endogenous
cytokines. Antitherapeutic antibodies (ATA) to host cytokines
may have physiological consequences depending on the nature
of the autoantibody, e.g., neutralizing, and potentially interfere
with in vitro cytokine measurement (de Jager and Rijkers,
2006). Therapeutic antibodies could elicit low-avidity hetero-
philic (nonspeciﬁc) antibodies in the animal that cross-react
and bridge the capture and detection antibodies in an
immunoassay and result in false-positive results. Interference
by heterophilic antibodies or ATA can be veriﬁed by depletion
of immunoglobulins from the specimen and rerunning the
specimen, correlating ATA to cytokine levels, and showing
nonlinearity upon dilution of the sample. These interferences
can also be removed by similar procedures (depletion of
dilution). In addition, some assay manufacturers include a
diluent that blocks interference from host antibodies.
Both protein therapeutics and small molecule agents have
the potential to induce autoantibodies against cytokines that
undergo a chronic course of stimulation by the therapeutic.
High afﬁnity autoantibodies against cytokines are observed in
both healthy and diseased human populations and have been
detected in rats and mice (de Lemos Rieper et al., 2009;
Watanabe et al., 2007). In humans, autoantibodies are found to
IL1, IL2, IL6, IL8, G-CSF, TNF-a, and VEGF. These
antibodies are often neutralizing and have been associated
with pathology related to depletion of the cytokine (de Lemos
Rieper et al., 2009). Autoantibodies most often will spuriously
decrease biomarker values and can be corrected by dilution of
the specimen (de Jager and Rijkers, 2006). In preclinical
toxicity studies, the presence of cytokine autoantibodies that
arise from chronic stimulation is not known, nor whether this
could contribute to a ‘‘false-negative’’ test result, or modiﬁca-
tion of the toxicologic response in vivo.
Species and strain differences in cytokine expression can
exert a considerable inﬂuence on the evaluation of cytokine
biomarkers of toxicity. The differences could be as rudimentary
as susceptibility to the toxicity itself. The strain resistance
variation of mice to bleomycin-induced pulmonary ﬁbrosis is
attributable in part to differences in the induction of cytokine
receptor expression in the lung (Cavarra et al., 2004). A log-
fold difference in TNF-a production in response to in vitro
splenocyte stimulation has been demonstrated between rat
strains (Warle et al., 2005). The availability of reagents has
allowed characterization of many of the wide ranging differ-
ences between human and mouse immune systems that impact
cytokine expression. Some of the underlying differences
include variations in immune cell subsets and localization,
receptor expression, signal transduction, and differences in
evolutionary retention and divergence of genes for cytokines
and chemokines in mouse compared with human (Mestas and
Hughes, 2004). Distinctions between human and rat, dog, and
nonhuman primate cytokine repertoire and responses are not as
well described (Piccotti et al., 2009).
The TGN1412 anti-CD28 molecule exempliﬁes the most
disastrous consequence of species differences in cytokine
response. Cynomologous macaques did not predict the
exaggerated immune stimulation (cytokine storm) experienced
in the phase I clinical trial (Suntharalingam et al., 2006).
However, studies examining species differences in the
immunostimulatory response to this biologic provide important
information for future guidances in preclinical safety assess-
ment of targets of this type. In subsequent in vitro lymphocyte
stimulation assays, macaque lymphocytes, while not showing
the 2–3 log induction of TNF-a and IFNc of human
lymphocytes, exhibited a modest 18-fold increase in IL6 and
IL5 (Muller and Brennan, 2009). A surrogate anti-rat-CD28
antibody (JJ316) also failed to elicit a cytokine storm in the rat
(Muller et al., 2008). The profound lymphopenia and
lymphocyte redistribution shown by human patients was
observed in the rat, in addition to the pan-T-cell activation.
Furthermore, sorted naı ¨ve and adopted effector T cells from
JJ316-treated rats had upregulated transcription of cytokines
(IFNc, IL17, and MCP-1) and surface expression of cell
activation markers. However, cytokine levels in rat serum
(IFNc and TNF-a) were only mildly elevated. Various rat
models with an immunostimulatory or autoimmune phenotype
also failed to exhibit a cytokine storm in response to anti-CD28
stimulation (Muller et al., 2008). Both the macaque and the rats
substantially underestimated the immunostimulation of
TGN1412 anti-CD28 in humans.
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tional toxicity study designs and thus are an important proving
ground for biomarker qualiﬁcation. Toxicity study design
factors can impact cytokine responses; therefore, robust study
controls are necessary to accurately attribute changes in
cytokine values to toxicity.
CYTOKINES AS BIOMARKERS OF TOXICITY
Cytokines have been rationally evaluated as biomarkers of
intended and unintended inﬂammation and immunomodulation or
uncovered by systems biology approaches during toxicity
biomarker discovery. Biomarker exploration typically analyzes
early time points to reveal the temporal response and by doing so
will detect proximal pathophysiological processes. Candidate
markers that are signiﬁcantly changed in biomarker discovery
comprise components of on-target or off-target pathways, tissue-
speciﬁc response to injury, and/or represent a general process
once the cell injury has occurred. For an uncomplicated toxicity
limited to one organ system or one mechanism, an early marker
of a general process such as inﬂammation may directly correlate
with the toxicity and have adequate speciﬁcity for the tissue
injury. Speciﬁcity of an inﬂammatory biomarker becomes
difﬁcult to attain when there are multiple mechanisms of toxicity
and/or organ involvement that could affect cytokine values.
Typical scenarios are decreased leukocyte numbers affecting
cytokine production, liver injury that impairs synthesis of binding
proteins and clearance, renal dysfunction affecting clearance, and
compromise of the intestinal barrier leading to endotoxin
translocation and stimulation of inﬂammatory mediators. The
hallmark cytokines for several pathologic responses observed in
toxicity studies (Table 2) exemplify several concepts of cytokine
biology, namely that primary cytokines are key drivers of
inﬂammation and immunity and the expected overlap reﬂects
cytokine pleiotropy and redundancy of action. Changes in the
toxic stimulus (dose and pharmacologic variables), site of action,
and coexisting toxicities may provide an additional retinue of
cytokines for each pathologic response. In addition, these key
cytokines are frequently but not always detected in the blood.
Routine clinical pathology analyses, comprising clinical
chemistry, hematology, coagulation panels, and urinalysis,
constitute a powerful set of markers that usually capture
general processes of inﬂammation and tissue injury. On
occasion, these markers may not provide adequate sensitivity
for low-grade or focal inﬂammation or could be compromised
by coexisting toxicity, i.e., myelosuppression reducing the
number of neutrophils. This situation may yield a gap in
markers of tissue inﬂammation and repair. When no such gap
exists, critical evaluation of the cost beneﬁt of a new cytokine
marker in comparison with routine clinical pathology param-
eters is necessary. This comparison should include the
additional cost of analysis, strength of association with
the tissue damage, predictive value, and whether application
of the marker would translate to improved patient safety.
Correlation to the severity of tissue injury is an important
attribute of a toxicity biomarker. This is not always a character-
istic of proximal markers of disease, such as cytokines. Proximal
markers of toxicity could reﬂect the pharmacokinetics of the test
compound (peak serum concentration and exposure) more so
than sustained or distal disease processes that contribute largely
to structural damage and/or organ dysfunction. Lesions with a
subacute to chronic course, and a multidose regimen, may elicit
cyclic ﬂuctuations of cytokines that are not linearly related to the
histological ﬁndings. Moreover, counterregulatory changes to
cytokine release may result in abrogation, diminution, or an
altered time course of cytokines following multiple dosing of
a therapeutic. The level of IFNc, a PD and toxicity biomarker of
recombinant human IL12 administration, is maximal after the
ﬁrst dose and then markedly downregulated, concomitant with
increased expression of IL12 receptor (Rakhit et al.,1 9 9 9 ).
Furthermore, the decrease in an early mediator may not imply
that the lesion is resolving but rather connote a short circulating
half-life and systemic levels that do not reﬂect local concen-
trations and activity. Illustrating the latter point is the extensive
variability of a cytokine panel in patients with chronic
periodontal disease (Gorska et al.,2 0 0 3 ). Although tissue
cytokine levels correlate to disease severity by microscopic
examination of the gingiva, the overwhelming biological
(interindividual) variability in the disease population for serum
cytokines precluded their use as accurate diagnostic biomarkers
for this disease. This inherent and often unexplained biological
variability was also demonstrated in a clinical study of acute
experimental endotoxemia. There was up to a 10-fold range
in baseline and peak values of IL6 and TNF-a that was
unassociated with TNF genotype (Kovar et al.,2 0 0 7 ).
The strength of association with existing toxicity end points
is a key criterion in selecting single or multiple biomarkers.
Cytokines in a multiplex assay can be evaluated individually
TABLE 2
Commonly Modulated Blood Cytokines Associated with
Pathological Responses
Pathological response
a,b Cytokines
c
Acute-phase response IL1b, IL6, TNF-a
Cytokine storm/release IL2, IL6, IL8, IL10, IFNc, TNF-a
Fibrosis TGFb
Hemophagocytic syndrome IFNc, IL1b, IL6, TNF-a
Neutrophilic inﬂammation IL8, MIP-1, TNF-a
Systemic inﬂammatory response
syndrome
IL6, MCP-1, TNF-a
Th1 immune response IFNc, IL2, IL12
Th2 immune response IL4, IL5, IL6, IL10, IL13
aPathological responses observed in toxicity studies, includes inﬂammation,
immunity, and repair.
bDescriptions of immunostimulatory toxic responses are in Gribble et al.
(2007).
cCytokines that drive the response and are most commonly at detectable
systemic levels.
12 TARRANTor, by using combinatorial analysis, as a group. Multivariate
statistical techniques, with correction for multiple tests, can be
applied to the analysis of these large data sets. In addition,
bioinformatics techniques such as principal component analy-
sis (Wong et al., 2008) and hierarchical cluster analysis (Khan
et al., 2009; Panelli et al., 2004) can be used to detect
relationships between multiple analytes and between speci-
mens. By clustering similarly responding cytokines, a biolog-
ical response may become evident. Hence, these methods are
a strategy to contend with the redundancy and pleiotropic
action of cytokines. Quality data (controls, preanalytical and
analytical variability reduced) and statistical methods to control
false positives are essential prerequisites to discovering true
associations.
Serum cytokines have been considered for toxicities where
serum biomarkers are absent or inadequately premonitory, such
as drug-induced liver and vascular injury (Lacour et al., 2005)
(Kerns et al., 2005). There is, however, little published on the
utility of cytokine biomarkers in the assessment of these
toxicities to date. A study of acetaminophen overdose in
a clinical population demonstrated an increase in IL8, IL6, and
MCP-1 in the most severely affected patients (based on serum
ALT), yet only MCP-1 had a good correlation (R
2 ¼ 0.607)
over the range of severity (James et al., 2005). MCP-1 did not
show an association with serum acetaminophen level or the
Rumack-Matthew nomogram for estimating risk of hepatox-
icity after acetaminophen overdose (James et al., 2005).
Several phosphodiesterase IV (PDE4) inhibitors induce
inﬂammatory vascular injury in preclinical species. Serum
levels of cytokines (IL6, CINC-1, and VEGF), acute-phase
response proteins (haptoglobin and a1 acid glycoprotein), and
neutrophils show time- and dose-related increases and a re-
lationship to histological severity of the vasculitis caused by
the two PDE4 inhibitors under examination, SCH 351591 and
SCH 534385 (Weaver et al., 2008). However, drug-induced
vasculitis is not observed for all drugs inhibiting this target,
possibly relating to differences in drug selectivity between
phosphodiesterase subtypes (Dietsch et al., 2006). Toxicity
proﬁling of the PDE4 inhibitor IC542 showed inﬂammation in
multiple tissues without prominent vasculitis, yet an overlap in
the repertoire of biomarkers for IC542-induced inﬂammation
and those previously described for SCH 351591/SCH 53438-
induced vasculitis (Dietsch et al.,2 0 0 6 ). Accordingly, the
utility of inﬂammatory markers as an indication of vasculitis
cannot be generalized for all PDE4 inhibitors and is not
surprising given the lack of speciﬁcity of these biomarkers.
Measurement of serum cytokines may have most utility in
immunotoxicty studies that evaluate intended or unintended
inﬂammation and immunomodulation produced by therapeutics.
Toxicities associated with immunostimulatory molecules include
the acute-phase response, cytokine storm (also known as
cytokine release syndrome, systemic inﬂammatory response,
and multiple organ dysfunction syndrome), vascular leak
syndrome, vasculitis, antibody-mediated cytopenia, hemopha-
gocytic syndrome, immune complex disease, local tissue injury,
e.g., liver, kidney, skin, lung, and ﬁrst dose effect (Gribble et al.,
2007). There is a dearth of published data on the correlation and
accuracy, i.e., predictive values, receiver operator characteristics,
etc., of select serum cytokines and speciﬁc toxicities. Concerns
in the industry have been expressed over the signiﬁcance of
small magnitude changes of cytokines and the lack of deﬁned
dose-response thresholds for pharmacology (if on target),
reversible cell injury, and toxicity that translates to the clinic
(Piccotti et al.,2 0 0 9 ). Given that adverse events with
immunostimulatory agents are usually acute and predicated on
changes in standard, i.e., accepted by regulatory bodies,
symptomatology, physical exam, diagnostic, and laboratory
parameters, the measurement of cytokines may provide post hoc
mechanistic data more so than premonitory markers sufﬁcient to
guide intervention or dose modulation ahead of adverse events.
Successful use of a cytokine biomarker to guide a program is
demonstrated by the monitoring of serum IFNc for the
immunostimulatory toxicity associated with iv recombinant
human IL12 (rHuIL12) administration. In humans, cynomolgus
monkeys, and mice, species-speciﬁc rIL12 resulted in large
modulations of serum IFNc corresponding to gastrointestinal
toxicity, multiorgan dysfunction, and death. Cytokines were
measured 24 h after each daily dose. Interestingly, mice and
humans showed similar IFNc response kinetics with a peak after
the second or third dose (Leonard et al.,1 9 9 7 ). Serious adverse
events in patients occurred after two daily iv doses of rHIL12. It
was not investigated whether IFNc measurement prior to 24 h
after ﬁrst dose would have proven to be premonitory for these
adverse events. By using IFNc as a marker of toxicity, schedule
changes, route changes, and further mechanistic investigations
were made possible (Leonard et al.,1 9 9 7 ; Rakhit et al.,1 9 9 9 ).
Recombinant human IL18 is an immunostimulatory therapeutic
anticipated to have similar activity to IL12 and potentially
similar toxicity. The toxicity proﬁle of ﬁve daily iv infusions of
recombinant IL18 in the clinic was monitored by measuring
IFNc, granulocyte-macrophage colony-stimulating factor (GM-
CSF) and IL12 prior to the ﬁrst dose, 24 h after each dose, and at
6 and 12 h after the ﬁrst and ﬁfth dose. Peaks of IFNc and GM-
CSF occurred 6 h after the ﬁrst dose and resolved by 24 h
postdose. Blood level of IFNc was lower than that measured at
a similar time point after rHuIL12 and corresponded to the
milder toxicity of rHuIL18 (Robertson et al.,2 0 0 6 ).
Current guidance documents for preclinical ﬁling of pharma-
ceuticals (S8: Immunotoxicity Studies for Human Pharmaceut-
icals) address only unintended immunomodulation and advocate
additional immunotoxicity studies to characterize risk
(International Conference on Harmonization, 2006). Broadly,
immunotoxicity evaluations advanced by the S8 guidance
include ex vivo immunophenotyping of blood cells, immune
cell function in vitro, in vivo immune challenges (e.g., T-cell–
dependent immune response), and host resistance, as well as
extended histopathological examination of lymphoid tissue in
standard animal toxicity studies. Serum cytokine measurement
BLOOD CYTOKINES AS BIOMARKERS 13does not have industry-wide adoption in ﬁrst tier immune
function evaluations (Piccotti et al.,2 0 0 9 ). Concerns over
species translation (or sensitivity) and detection of immunomo-
dulation have in part driven alternative approaches to risk
assessment (Muller and Brennan, 2009). Regulatory guidance
for selecting a safe starting dose in human trials now includes the
minimal anticipated biological response calculated by pharma-
cokinetics and PD markers in addition to a no adverse effect
level determined in preclinical in vivo toxicity studies (EMEA,
2007).
CONCLUSIONS
With the encouragement of regulatory agencies to improve
development of innovative and safe drugs, extant gaps in
toxicity biomarkers are being addressed. Cytokines are not
uncommonly identiﬁed in this push to improve biomarker
repertoire, facilitated in part by the excellent technical advances
in multiplexed immunoassays, and their role as integral
components of inﬂammation, repair, and immunomodulation
processes in toxicity. Ultimately, toxicity biomarkers are most
useful when sensitive, speciﬁc, and predictive, and having
kinetics consonant with tissue injury, tissue dysfunction, or the
mechanism of toxicity. Cytokine ﬂuctuations can be sensitive
but may be too acute (proximal) to correlate with the severity of
tissue injury when distal processes dominate. When cytokines
are key drivers of acute toxicity, namely immunostimulation,
their use as biomarkers is more successful. In spite of this,
biological variability, assay sensitivity, and short half-life still
remain obstacles. The early appearance of cytokines and short
half-life offer deﬁnite advantages as mechanistic markers and in
modeling exposure-activity-toxicity relationships.
Practically, investigators should use several platforms for
cytokine biomarker discovery, only directly compare results
across studies from the same assay, and validate all assays in-
house to determine assay performance on the species specimen
of interest. Using a multiplex assay as a screening tool is
undeniably useful and a good starting point; however, an
additional multiplex or single analyte assay(s) should be
completed to conﬁrm initial ﬁndings.
Multiplexes also facilitate the testing of cytokine panels as an
innovative solution to toxicity biomarker discovery and
mechanistic understanding of toxicity. Combinatorial analysis
of cytokine biomarker panels could exploit a unique pattern of
‘‘general’’ markers to provide speciﬁcity. This is a departure
from toxicity detection with one biomarker in isolation or
subjective pattern recognition. However, there are few examples
of this combinatorial approach used in preclinical risk
assessment so far; therefore, analytical validation and robust
qualiﬁcation will require some trail blazing and commitment.
We have amassed a huge amount of knowledge that informs
our interpretation of traditional serum biomarkers, including
the timing of specimen collection, standardized measurement,
species differences and interpretation of changes in the context
of health (biological variability), toxicity, and multiple toxicities.
We need to actively seek or generate this information when
assessing serum cytokines as safety biomarkers. Understanding
the complex pathophysiology of multiple coexisting toxicities
and taking a ‘‘whole’’ animal integrated perspective is vital to
judge the value of a cytokine during biomarker qualiﬁcation.
With the expected overlap of cytokines seen during different
pathologic processes and the inherent biological variability of
systemic levels of cytokines, identiﬁcation of a speciﬁc cytokine
or panel of cytokines, together with setting a threshold (decision
limit) of systemic levels for toxicity, is challenging. Few
cytokine biomarkers that are predictive of speciﬁc tissue
toxicities have emerged as yet.
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